- Email: [email protected]
CHARACTERISTICS AND CLINICAL OUTCOMES OF PATIENTS UNDERGOING SUBCUTANEOUS VERSUS TRANSVENOUS SINGLE CHAMBER ICD PLACEMENT
860 JACC April 5, 2016 Volume 67, Issue 13
Arrhythmias and Clinical EP CHARACTERISTICS AND CLINICAL OUTCOMES OF PATIENTS UNDERGOING SUBCUTANEOUS VERSUS TRANSVENOUS SINGLE CHAMBER ICD PLACEMENT Poster Contributions Poster Area, South Hall A1 Monday, April 04, 2016, 9:45 a.m.-10:30 a.m. Session Title: Clinical Care of Patients With Implanted Devices Abstract Category: 18. Arrhythmias and Clinical EP: Devices Presentation Number: 1266-327 Authors: Ali Mithani, Heaton Kath, Eben Eno, Karim Nathan, Julie Field, Krystal Hunter, Matthew Ortman, John Andriulli, Andrea Russo, Cooper University Hospital, Camden, NJ, USA
Background: In 2012, the first totally Subcutaneous Implantable Cardioverter-Defibrillator (S-ICD) was approved by the Food and Drug Administration (FDA). A potential benefit of this device is that it does not involve placing leads “in” or “on” the heart, potentially reducing complications.
Methods: Seventy-one pts underwent S-ICD implantation between 10/22/2012 and 1/22/2015. During this period of time, 71 pts with TV-ICDs were matched to S-ICD pts using NCDR ICD Registry Data based on dialysis status, age, and gender. Intra- and post-operative complications were examined within the first 180 days following implantation..
Results: Pts with S-ICDs had higher creatinine (2.32 vs. 1.20, p <0.05) and were more likely to be on chronic dialysis (22.5% vs. 9.9%, p=0.004) than TV-ICD ps. Three pts in the TV-ICD and 7 pts in the S-ICD group had prior TV device infection requiring explant. Two pts in the TV-ICD and 13 ps in the S_ICD group had a previous CVA/TIA (p=0.007). Five pts experienced 6 complications in TV-ICD group and 2 pts experienced 4 complications in SQ-ICD group, p = 0.453 (See Complications Table). Conclusions: In this retrospective matched single center cohort study, there was no significant difference in implantation complications in pts receiving single chamber TV-ICDs compared to S-ICDs within 6 months following implantation. This occurred despite more severe preexisting illness in the S-ICD group. Further investigation is needed to determine outcomes after longer-term follow-up.
Arrhythmias and Clinical EP CHARACTERISTICS AND CLINICAL OUTCOMES OF PATIENTS UNDERGOING SUBCUTANEOUS VERSUS TRANSVENOUS SINGLE CHAMBER ICD PLACEMENT Poster Contributions Poster Area, South Hall A1 Monday, April 04, 2016, 9:45 a.m.-10:30 a.m. Session Title: Clinical Care of Patients With Implanted Devices Abstract Category: 18. Arrhythmias and Clinical EP: Devices Presentation Number: 1266-327 Authors: Ali Mithani, Heaton Kath, Eben Eno, Karim Nathan, Julie Field, Krystal Hunter, Matthew Ortman, John Andriulli, Andrea Russo, Cooper University Hospital, Camden, NJ, USA
Background: In 2012, the first totally Subcutaneous Implantable Cardioverter-Defibrillator (S-ICD) was approved by the Food and Drug Administration (FDA). A potential benefit of this device is that it does not involve placing leads “in” or “on” the heart, potentially reducing complications.
Methods: Seventy-one pts underwent S-ICD implantation between 10/22/2012 and 1/22/2015. During this period of time, 71 pts with TV-ICDs were matched to S-ICD pts using NCDR ICD Registry Data based on dialysis status, age, and gender. Intra- and post-operative complications were examined within the first 180 days following implantation..
Results: Pts with S-ICDs had higher creatinine (2.32 vs. 1.20, p <0.05) and were more likely to be on chronic dialysis (22.5% vs. 9.9%, p=0.004) than TV-ICD ps. Three pts in the TV-ICD and 7 pts in the S-ICD group had prior TV device infection requiring explant. Two pts in the TV-ICD and 13 ps in the S_ICD group had a previous CVA/TIA (p=0.007). Five pts experienced 6 complications in TV-ICD group and 2 pts experienced 4 complications in SQ-ICD group, p = 0.453 (See Complications Table). Conclusions: In this retrospective matched single center cohort study, there was no significant difference in implantation complications in pts receiving single chamber TV-ICDs compared to S-ICDs within 6 months following implantation. This occurred despite more severe preexisting illness in the S-ICD group. Further investigation is needed to determine outcomes after longer-term follow-up.